Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2015 4
2016 3
2017 2
2018 3
2019 1
2020 3
2021 18
2022 32
2023 39
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.
Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Paskeh MDA, et al. Among authors: entezari m. J Hematol Oncol. 2022 Jun 28;15(1):83. doi: 10.1186/s13045-022-01305-4. J Hematol Oncol. 2022. PMID: 35765040 Free PMC article. Review.
STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response.
Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. Sadrkhanloo M, et al. Among authors: entezari m. Pharmacol Res. 2022 Aug;182:106311. doi: 10.1016/j.phrs.2022.106311. Epub 2022 Jun 15. Pharmacol Res. 2022. PMID: 35716914 Review.
EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions.
Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, Kakavand A, Tavakolpournegari A, Saebfar H, Heidari H, Salimimoghadam S, Entezari M, Taheriazam A, Hushmandi K. Hashemi M, et al. Among authors: entezari m. Biomed Pharmacother. 2022 Nov;155:113774. doi: 10.1016/j.biopha.2022.113774. Epub 2022 Oct 3. Biomed Pharmacother. 2022. PMID: 36271556 Free article. Review.
AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation.
Entezari M, Hashemi D, Taheriazam A, Zabolian A, Mohammadi S, Fakhri F, Hashemi M, Hushmandi K, Ashrafizadeh M, Zarrabi A, Ertas YN, Mirzaei S, Samarghandian S. Entezari M, et al. Biomed Pharmacother. 2022 Feb;146:112563. doi: 10.1016/j.biopha.2021.112563. Epub 2021 Dec 29. Biomed Pharmacother. 2022. PMID: 35062059 Free article. Review.
Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions.
Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, Ahmadi F, Salimimoghadam S, Aref AR, Zandieh MA, Entezari M, Taheriazam A, Hushmandi K. Hashemi M, et al. Among authors: entezari m. Biomed Pharmacother. 2023 Feb;158:114204. doi: 10.1016/j.biopha.2022.114204. Epub 2023 Jan 4. Biomed Pharmacother. 2023. PMID: 36916430 Free article. Review.
Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance.
Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B, Zandieh MA, Behroozaghdam M, Mirzaei S, Hushmandi K, Nabavi N, Salimimoghadam S, Ren J, Rashidi M, Raesi R, Taheriazam A, Alexiou A, Papadakis M, Tan SC. Hashemi M, et al. Among authors: entezari m. Cell Mol Biol Lett. 2023 Apr 21;28(1):33. doi: 10.1186/s11658-023-00438-9. Cell Mol Biol Lett. 2023. PMID: 37085753 Free PMC article. Review.
Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective.
Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, Ghanbarirad M, Haghighatfard A, Behroozaghdam M, Khorrami R, Nabavi N, Ren J, Reiter RJ, Salimimoghadam S, Rashidi M, Hushmandi K, Taheriazam A, Entezari M. Hashemi M, et al. Among authors: entezari m. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166714. doi: 10.1016/j.bbadis.2023.166714. Epub 2023 Apr 5. Biochim Biophys Acta Mol Basis Dis. 2023. PMID: 37028606 Review.
Non-coding RNA-based therapeutics in cancer therapy: An emphasis on Wnt/β-catenin control.
Taheriazam A, Bayanzadeh SD, Heydari Farahani M, Mojtabavi S, Zandieh MA, Gholami S, Heydargoy MH, Jamali Hondori M, Kangarloo Z, Behroozaghdam M, Khorrami R, Sheikh Beig Goharrizi MA, Salimimoghadam S, Rashidi M, Hushmandi K, Entezari M, Hashemi M. Taheriazam A, et al. Among authors: entezari m. Eur J Pharmacol. 2023 Jul 15;951:175781. doi: 10.1016/j.ejphar.2023.175781. Epub 2023 May 11. Eur J Pharmacol. 2023. PMID: 37179043 Review.
Targeting PI3K/Akt signaling in prostate cancer therapy.
Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S, Hejazi ES, Aboutalebi M, Gholamrezaie H, Saebfar H, Salimimoghadam S, Mirzaei S, Entezari M, Samarghandian S. Hashemi M, et al. Among authors: entezari m. J Cell Commun Signal. 2023 Sep;17(3):423-443. doi: 10.1007/s12079-022-00702-1. Epub 2022 Nov 11. J Cell Commun Signal. 2023. PMID: 36367667 Free PMC article. Review.
102 results